MX2009003002A - Formulaciones de tensioactivos pulmonares y metodos para promover la aclaracion del moco. - Google Patents

Formulaciones de tensioactivos pulmonares y metodos para promover la aclaracion del moco.

Info

Publication number
MX2009003002A
MX2009003002A MX2009003002A MX2009003002A MX2009003002A MX 2009003002 A MX2009003002 A MX 2009003002A MX 2009003002 A MX2009003002 A MX 2009003002A MX 2009003002 A MX2009003002 A MX 2009003002A MX 2009003002 A MX2009003002 A MX 2009003002A
Authority
MX
Mexico
Prior art keywords
methods
mucus clearance
pulmonary surfactant
pulmonary
surfactant formulations
Prior art date
Application number
MX2009003002A
Other languages
English (en)
Spanish (es)
Inventor
Mark E Johnson
Robert Segal
Thomas Hofmann
Robert J Capetola
Original Assignee
Discovery Lab Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Discovery Lab Inc filed Critical Discovery Lab Inc
Publication of MX2009003002A publication Critical patent/MX2009003002A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/10—Expectorants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/12—Mucolytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dispersion Chemistry (AREA)
  • Otolaryngology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
MX2009003002A 2006-09-19 2007-09-19 Formulaciones de tensioactivos pulmonares y metodos para promover la aclaracion del moco. MX2009003002A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US84599106P 2006-09-19 2006-09-19
PCT/US2007/020260 WO2008036293A1 (en) 2006-09-19 2007-09-19 Pulmonary surfactant formulations and methods for promoting mucus clearance

Publications (1)

Publication Number Publication Date
MX2009003002A true MX2009003002A (es) 2009-06-01

Family

ID=38921793

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009003002A MX2009003002A (es) 2006-09-19 2007-09-19 Formulaciones de tensioactivos pulmonares y metodos para promover la aclaracion del moco.

Country Status (11)

Country Link
US (1) US8221772B2 (enExample)
EP (1) EP2063903A1 (enExample)
JP (1) JP2010503731A (enExample)
KR (1) KR20090060348A (enExample)
AU (1) AU2007297691B2 (enExample)
BR (1) BRPI0717177A2 (enExample)
CA (1) CA2663795A1 (enExample)
MX (1) MX2009003002A (enExample)
RU (1) RU2455021C2 (enExample)
WO (1) WO2008036293A1 (enExample)
ZA (1) ZA200902487B (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8669418B2 (en) 2005-12-22 2014-03-11 Vib Vzw Means and methods for mediating protein interference
EP2211956A4 (en) * 2007-10-10 2014-07-09 Parion Sciences Inc DISPOSAL OF OSMOLYTES WITH A NOSE CANNULA
DK2459231T3 (en) 2009-07-31 2016-09-05 Ethris Gmbh RNA with a combination of unmodified and modified nucleotides for protein expression
EA201300255A1 (ru) * 2010-08-23 2013-06-28 Такеда Гмбх Увлажненные частицы, содержащие терапевтически активное вещество
US8945605B2 (en) 2011-06-07 2015-02-03 Parion Sciences, Inc. Aerosol delivery systems, compositions and methods
US8778383B2 (en) * 2011-06-07 2014-07-15 Parion Sciences, Inc. Methods of treatment
WO2015061412A1 (en) * 2013-10-22 2015-04-30 The Scripps Research Institute Methods and compositions for promoting bronchioli dilatation
GB201406225D0 (en) * 2014-04-07 2014-05-21 Hall Roderick L Treatment for respiratory disease
CA2945604C (en) * 2014-08-08 2022-08-23 Shenzhen Hightide Biopharmaceutical, Ltd. Liquid formulation compositions, medicament delivery devices, and methods of preparation and use thereof
WO2017205383A1 (en) * 2016-05-23 2017-11-30 University Of Iowa Research Foundation Method of treating cystic fibrosis airway disease
US20190231686A1 (en) * 2016-07-16 2019-08-01 Lauranell Harrison BURCH Methods for treating cystic fibrosis and other diseases affecting mucosal surfaces
WO2018064529A1 (en) * 2016-09-29 2018-04-05 The Uab Research Foundation Methods and compositions for increasing mucus clearance
WO2018206732A1 (en) 2017-05-09 2018-11-15 Vib Vzw Means and methods for treating bacterial infections
EP3727353A4 (en) * 2017-12-21 2021-10-13 Civitas Therapeutics, Inc. SURFACTANT FORMULATIONS FOR INHALATION
US12427273B1 (en) 2020-05-15 2025-09-30 John E. Boyd Methods for treating respiratory distress and compositions for use in the same
GB202202297D0 (en) 2022-02-21 2022-04-06 Verona Pharma Plc Formulation production process
US12194045B1 (en) 2023-06-26 2025-01-14 Verona Pharma Plc Particulate composition
KR20250153517A (ko) 2024-04-18 2025-10-27 민현홍 신생아 호흡 곤란 증후군을 앓고 있는 조산아의 폐 전달을 개선하기 위한 미세기포 함유 에어로졸
WO2025231023A1 (en) * 2024-04-29 2025-11-06 Virginia Commonwealth University Aerosol surfactant therapy (ast) for respiratory distress syndrome (rds)

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5840527A (en) * 1984-12-11 1998-11-24 Byk Gulden Lomberg Chemische Fabrik Gmbh Recombinant alveolar surfactant protein
US4659805A (en) 1984-12-11 1987-04-21 California Biotechnology, Inc. Recombinant alveolar surfactant protein
US4918161A (en) * 1985-09-26 1990-04-17 Genetics Institute, Inc. Low molecular weight pulmonary surfactant proteins
IT1203873B (it) * 1987-04-08 1989-02-23 Chiesi Farma Spa Composizioni farmaceutiche che lo surfattante polmonare naturale, contengono. metodo di preparazione e
WO1989004326A1 (en) 1987-11-04 1989-05-18 California Biotechnology Inc. Alveolar surfactant proteins
US5260273A (en) * 1988-01-06 1993-11-09 The Scripps Research Institute Pulmonary surfactant protein and related polypeptide
US6613734B2 (en) * 1988-01-06 2003-09-02 The Scripps Research Institute Peptides-containing liposomal surfactants
US5164369A (en) * 1988-01-06 1992-11-17 The Scripps Research Institute Pulmonary surfactant protein and related polypeptide
US6013619A (en) * 1988-01-06 2000-01-11 The Scripps Research Institute Pulmonary surfactants and therapeutic uses, including pulmonary lavage
US4861756A (en) * 1988-03-08 1989-08-29 Merrell Dow Pharmaceuticals Inc. Synthetic pulmonary surfactant
SE8803713D0 (sv) * 1988-10-18 1988-10-18 Kabigen Ab Biologically active lipoprotein and its use
US5006343A (en) * 1988-12-29 1991-04-09 Benson Bradley J Pulmonary administration of pharmaceutically active substances
US5238920A (en) * 1989-08-22 1993-08-24 Abbott Laboratories Pulmonary surfactant protein fragments
EP0458167B1 (en) * 1990-05-21 1997-04-23 Abbott Laboratories Fatty acid-pulmonary surfactant conjugates
US5272252A (en) * 1991-11-04 1993-12-21 Merrell Dow Pharmaceuticals Inc. Synthetic lung surfactant having antioxidant properties
ATE231522T1 (de) * 1992-04-10 2003-02-15 Abbott Lab Fragmente eines oberflächenaktiven lungenproteins
US5302481A (en) * 1993-06-07 1994-04-12 Xerox Corporation Toner compositions with negative charge enhancing complexes
PT733645E (pt) * 1993-12-08 2003-07-31 Mitsubishi Pharma Corp Novo peptido sintetico tensoactivo pulmonar que o contem e medicamento para sindroma da insuficiencia respiratoria
DE4418936A1 (de) * 1994-05-31 1996-02-08 Byk Gulden Lomberg Chem Fab Polypeptid
DE4434629C1 (de) * 1994-09-28 1996-06-27 Byk Gulden Lomberg Chem Fab Zusammensetzungen zur Behandlung von IRDS und ARDS
US5508269A (en) * 1994-10-19 1996-04-16 Pathogenesis Corporation Aminoglycoside formulation for aerosolization
US5767068A (en) * 1997-02-13 1998-06-16 Pathogenesis Corporation Pure biologically active colistin, its components and a colistin formulation for treatment of pulmonary infections
US5925334A (en) * 1997-08-27 1999-07-20 Rubin; Bruce K. Use of surface active agents to promote mucus clearance
US7198635B2 (en) * 2000-10-17 2007-04-03 Asthmatx, Inc. Modification of airways by application of energy
US6926911B1 (en) * 1998-12-22 2005-08-09 The University Of North Carolina At Chapel Hill Compounds and methods for the treatment of airway diseases and for the delivery of airway drugs
JP3819239B2 (ja) * 1998-12-22 2006-09-06 バイエル アクチェンゲゼルシャフト 粘膜線毛クリアランスの速度を促進する方法
RU2149015C1 (ru) * 1999-07-01 2000-05-20 Центральный научно-исследовательский рентгенорадиологический институт Способ лечения постнатальных пневмоний у новорожденных
RU2149014C1 (ru) * 1999-07-01 2000-05-20 Центральный научно-исследовательский рентгенорадиологический институт Способ лечения острых бронхопневмоний, осложненных ателектазом
DE10006179A1 (de) * 2000-02-11 2001-08-23 Byk Gulden Lomberg Chem Fab Neue Verwendung von Lungensurfactant zur Prophylaxe und Behandlung von chronischen Lungenerkrankungen
US6660833B1 (en) * 2000-02-29 2003-12-09 Harbor-Ucla Research And Education Institute Respiratory distress syndrome therapy with peptide analogs of human SP-B
US7422743B2 (en) * 2000-05-10 2008-09-09 Schering Corporation Mammalian receptor protein DCRS5;methods of treatment
CA2382133C (en) * 2000-05-10 2010-11-23 Alliance Pharmaceutical Corporation Phospholipid-based powders for drug delivery
EP1238680B1 (en) * 2001-03-05 2003-12-10 Ivo Pera Inhaling device for dispersing powdered medicaments contained in a capsule through the respiratory tract
WO2002092154A1 (en) * 2001-04-26 2002-11-21 New England Pharmaceuticals, Inc. Metered dose delivery device for liquid and powder agents
RU2213746C1 (ru) * 2002-02-15 2003-10-10 Научно-исследовательский институт физико-химической медицины Компонент, обеспечивающий поверхностно-активные свойства композиций - аналогов препаратов для заместительной сурфактантной терапии легочных заболеваний
RU2198670C1 (ru) * 2002-02-19 2003-02-20 ООО "Биосурф" Способ получения сурфактанта из легких крупного рогатого скота
GB0327723D0 (en) * 2003-09-15 2003-12-31 Vectura Ltd Pharmaceutical compositions
AU2004296206A1 (en) * 2003-12-04 2005-06-23 The Scripps Research Institute Treatment and preventions of asthma
EP1755720A1 (en) * 2004-05-20 2007-02-28 Discovery Laboratories, Inc. Methods , systems and devices for noninvasive pulmonary delivery
EP1781323B1 (en) * 2004-08-06 2010-02-17 Nycomed GmbH Composition comprising a pulmonary surfactant and a tnf-derived peptide
CA2579037A1 (en) 2004-08-27 2006-03-09 Discovery Laboratories, Inc. Methods, systems and devices for noninvasive pulmonary delivery
US7582312B2 (en) 2004-11-15 2009-09-01 Discovery Laboratories, Inc. Methods to produce lung surfactant formulations via lyophilization and formulations and uses thereof
US8337815B2 (en) * 2004-12-23 2012-12-25 Discovery Laboratories, Inc. Pulmonary surfactant formulations
ES2380046T3 (es) * 2005-01-06 2012-05-08 Discovery Laboratories, Inc. Régimen para el tratamiento con tensioactivos para tratar o prevenir la displasia broncopulmonar

Also Published As

Publication number Publication date
JP2010503731A (ja) 2010-02-04
EP2063903A1 (en) 2009-06-03
RU2009114825A (ru) 2010-10-27
WO2008036293A1 (en) 2008-03-27
ZA200902487B (en) 2010-07-28
US8221772B2 (en) 2012-07-17
AU2007297691A1 (en) 2008-03-27
RU2455021C2 (ru) 2012-07-10
US20080199410A1 (en) 2008-08-21
KR20090060348A (ko) 2009-06-11
CA2663795A1 (en) 2008-03-27
BRPI0717177A2 (pt) 2013-10-08
AU2007297691B2 (en) 2013-12-19

Similar Documents

Publication Publication Date Title
MX2009003002A (es) Formulaciones de tensioactivos pulmonares y metodos para promover la aclaracion del moco.
NO20090068L (no) Aktive agent formuleringer, fremstillingsmetoder, og anvendelsesmetoder
CL2020000468A1 (es) Uso de una formulación estable que comprende una enzima de reemplazo para la enzima lisosomal (divisional solicitud 201801220)
WO2007125545A3 (en) Transmucosal composition
PE20080658A1 (es) Formulaciones de metilnaltrexona en forma de polvo seco
NO20064584L (no) Tetrahydropyridoindolderivater
CR10408A (es) Composiciones novedosas para el trastornos del cabello y procedimiento de preparacion de las mismas
WO2008151235A3 (en) Compositions for delivering medicaments into the lungs, uses thereof
BR112014006220A2 (pt) composições de galacto-ramnogalacturonato para o tratamento de esteatohepatite não alcoólica e de doença de gordura no fígado não alcoólica
WO2006096434A3 (en) Pharmaceutical compositions for the treatment and/or prevention of anxiety disorders
NO20060978L (no) Farmasoytiske blandingr for behandling av prematur ejakulasjon ved pulmonal inhalering
WO2008039989A3 (en) Formulations of dnase and methods of use thereof
DE602005021770D1 (de) Indol-1-yl-essigsäurederivate
CO6300964A2 (es) Una composicion farmaceutica que comprende una combinacion de un agente quimioterapeutico y un anticuerpo 3 antiglipicano
CR10495A (es) Composicion que comprende por lo menos un alcohol alifatico superior y un extracto de griffonia simplicifolia
MX350595B (es) Composiciones organicas para tratar enfermedades relacionadas con beta-enac.
SI1933809T1 (sl) Sestavki za mazalno dajanje
WO2006078424A3 (en) Polyherbal compositions and methods for treating viral infections
WO2008099144A3 (en) Tgf-beta stimulant and further agent to reduce side effects
CO6220945A2 (es) Uso de una composicion que comprende formoterol y dipropianato de beclometasona para la prevencion y/o tratamiento de una exacerbacion de asma
MX2009005798A (es) Recuperacion de apoplejia.
WO2007002836A3 (en) Methods and compositions for the prevention and treatment of kidney disease
NO20075758L (no) Polymorfer av 3-0-(3',3'-dimetylsuccinyl) betulin syre di-N-metyl-D-glukamin
EP1968561B8 (en) Treatment of diabetic nephropathy
WO2006115770A3 (en) Orally disintegrating pharmaceutical tablet formulations of olanzapine

Legal Events

Date Code Title Description
FG Grant or registration